刘润哲, 宋俊科, 刘艾林, 杜冠华*. 人工智能在基于配体和受体结构的药物筛选中的应用进展J. 药学学报, 2021,56(8): 2136-2145. doi: 10.16438/j.0513-4870.2021-0052
引用本文: 刘润哲, 宋俊科, 刘艾林, 杜冠华*. 人工智能在基于配体和受体结构的药物筛选中的应用进展J. 药学学报, 2021,56(8): 2136-2145. doi: 10.16438/j.0513-4870.2021-0052
LIU Run-zhe, SONG Jun-ke, LIU Ai-lin, DU Guan-hua*. Progress on the application of artificial intelligence technology in ligand-based and receptor structure-based drug screeningJ. Acta Pharmaceutica Sinica, 2021,56(8): 2136-2145. doi: 10.16438/j.0513-4870.2021-0052
Citation: LIU Run-zhe, SONG Jun-ke, LIU Ai-lin, DU Guan-hua*. Progress on the application of artificial intelligence technology in ligand-based and receptor structure-based drug screeningJ. Acta Pharmaceutica Sinica, 2021,56(8): 2136-2145. doi: 10.16438/j.0513-4870.2021-0052

人工智能在基于配体和受体结构的药物筛选中的应用进展

Progress on the application of artificial intelligence technology in ligand-based and receptor structure-based drug screening

  • 摘要: 人工智能技术在药物筛选中的应用日益广泛。本文介绍了人工智能技术的特点,着重从机器学习尤其是深度学习角度,按照基于配体和受体结构两个方面,总结了人工智能技术在药物筛选中的应用和进展,以及如何应用人工智能从这两个方面进行药物设计。本文也讨论了人工智能技术在药物虚拟筛选领域的主要局限性和挑战,对其发展前景作以展望。

     

    Abstract: Artificial intelligence technology is being widely applied in drug screening. This paper introduces the characteristics of artificial intelligence, and summarizes the application and progress of artificial intelligence technology especially deep learning in drug screening, from ligand-based and receptor structure-based aspects. This paper also introduces how to apply artificial intelligence to drug design from these two aspects. Finally, we discuss the main limitations, challenges, and prospects of artificial intelligence technology in the field of drug screening.

     

/

返回文章
返回